Tatva Chintan Pharma Complete Financial Statements
In FY2026, Tatva Chintan Pharma (TATVA) reported revenue ₹134 Cr, net profit ₹10 Cr and EPS ₹4.41, with a net profit margin of 7.5% and ROE of 1.3%. Full financial statements from FY2018 to FY2026 (9 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review TATVA earnings valuation to evaluate earnings-based valuation against sector peers.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
TATVA Revenue, Net Profit & EBITDA — Year-on-Year Growth
TATVA YoY (Mar 2025 vs Mar 2026) — revenue +22.9%, net profit +900.0%, EBITDA +180.0%, expenses +7.1%. For live price, earnings ratios and company overview, see Tatva Chintan Pharma share price screener.
TATVA Income Statement — Revenue, EBITDA & Net Profit
Tatva Chintan Pharma revenue ₹134 Cr, EBITDA ₹28 Cr, net profit ₹10 Cr, EPS ₹4.41 (2026) — net profit margin 7.5%. Explore TATVA true value to estimate fundamental worth using multiple valuation models.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Jun 2020 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 134 | 125 | 109 | 118 | 133 | 84 | 103 | 107 | 86 | 97 | 125 | 115 | 85 | 92 | 99 | 90 | 122 | 127 | 111 | 109 | 109 | 62 | 52 | 81 |
| Expenses | 106 | 101 | 99 | 100 | 106 | 78 | 83 | 93 | 79 | 76 | 112 | 93 | 73 | 79 | 77 | 73 | 103 | 88 | 84 | 81 | 81 | 54 | 41 | 56 |
| EBITDA | 28 | 23 | 10 | 19 | 27 | 6 | 20 | 14 | 7 | 21 | 14 | 22 | 12 | 13 | 22 | 17 | 19 | 39 | 27 | 28 | 29 | 8 | 11 | 25 |
| Operating Profit Margin % | 21.00% | 18.00% | 8.00% | 15.00% | 19.00% | 7.00% | 16.00% | 12.00% | 8.00% | 21.00% | 10.00% | 19.00% | 13.00% | 12.00% | 22.00% | 17.00% | 15.00% | 29.00% | 23.00% | 24.00% | 23.00% | 11.00% | 20.00% | 31.00% |
| Depreciation | 10 | 9 | 7 | 9 | 9 | 7 | 6 | 7 | 7 | 7 | 3 | 6 | 7 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Interest | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 17 | 14 | 2 | 9 | 18 | -1 | 14 | 7 | 0 | 11 | 8 | 13 | 5 | 9 | 19 | 14 | 14 | 35 | 24 | 24 | 26 | 6 | 8 | 23 |
| Tax | 6 | 4 | 1 | 3 | 3 | 0 | 4 | 2 | 0 | 3 | -9 | 4 | 2 | 2 | 2 | 4 | 3 | 3 | 3 | 1 | 3 | 2 | 2 | 2 |
| Net Profit | 10 | 10 | 1 | 7 | 15 | -1 | 10 | 5 | 0 | 8 | 17 | 10 | 4 | 7 | 18 | 10 | 12 | 32 | 21 | 23 | 23 | 4 | 7 | 21 |
| Earnings Per Share (₹) | 4.41 | 4.24 | 0.44 | 2.84 | 6.49 | -0.29 | 4.11 | 2.23 | 0.06 | 3.43 | 7.65 | 4.29 | 1.48 | 3.21 | 7.90 | 4.42 | 5.24 | 15.02 | 10.51 | 11.52 | 10.29 | 1.77 | 3.34 | 10.39 |
TATVA Balance Sheet — Assets, Liabilities & Shareholders' Equity
TATVA total assets ₹1,004 Cr, total equity ₹782 Cr, total liabilities ₹ Cr (2026) — ROE 1.3%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Total Assets | 1,004 | 836 | 819 | 759 | 658 | 315 | 249 | 188 | 0 |
| Current Assets | 350 | 265 | 298 | 312 | 436 | 184 | 133 | 114 | 0 |
| Fixed Assets | 634 | 526 | 427 | 196 | 160 | 120 | 111 | 67 | 0 |
| Capital Work in Progress | 23 | 27 | 77 | 231 | 52 | 10 | 5 | 6 | 0 |
| Investments | 196 | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 283 | 305 | 332 | 447 | 185 | 133 | 115 | 0 |
| LIABILITIES | |||||||||
| Total Liabilities | |||||||||
| Current Liabilities | 9 | 1 | 2 | 5 | 14 | 31 | 44 | 35 | 0 |
| Non-Current Liabilities | |||||||||
| SHAREHOLDERS' EQUITY | |||||||||
| Total Equity | 782 | 739 | 737 | 515 | 473 | 166 | 118 | 80 | 0 |
| Share Capital | 23 | 23 | 23 | 22 | 22 | 20 | 8 | 8 | 0 |
| Reserves & Surplus | 758 | 715 | 714 | 493 | 451 | 146 | 110 | 72 | 0 |
TATVA Cash Flow Statement — Operating, Investing & Financing
Tatva Chintan Pharma operating cash flow ₹25 Cr, investing ₹-65 Cr, financing ₹17 Cr, net cash flow ₹-24 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | 25 | 98 | 28 | 20 | 20 | 25 | 7 | 13 |
| Investing Activities | -65 | -121 | -101 | -197 | -21 | -40 | -17 | -30 |
| Financing Activities | 17 | 31 | 38 | 235 | -5 | 10 | 17 | 7 |
| Net Cash Flow | -24 | 8 | -36 | 59 | -6 | -5 | 8 | -10 |